Moreover, the use of a polyclonal antibody designed to block all the receptor components of AM (RAMP2, RAMP3, and CLR) decreased both proliferation and invasion of prostate cancer cells, tumor weight, metastasis, and lymphatic vasculature [180]. Here, DCLK3 is linked to prostate carcinoma.